Harnessing tumor immune checkpoints for autoimmune disease therapeutics. (PubMed, Front Immunol) - Sep 26, 2026 - "Clinical success with CTLA-4-Ig (abatacept) and emerging efficacy of PD-1 agonists (e.g., peresolimab) provide proof-of-concept that augmenting inhibitory signaling can ameliorate autoimmunity. Future progress will require multi-omics profiling, biomarker-driven stratification, and next-generation agonist design. IC-targeted strategies hold promises but demand context-aware, mechanistically informed development for broad clinical impact in ADs."
IO biomarker • Journal • Review • Immunology • Oncology • Transplantation • HAVCR2 • LAG3 • PD-1 • TIGIT
|
|
Guobo Shen; Hanmei Yang; Na Xie; Ping Zhang; Yi Wu
|